Evolus (EOLS) Stifel 2026 Healthcare Conference 2026 summary

Portfolio growth and expansion

• Jeuveau established a double-digit U.S. toxin share; the portfolio has expanded with Evolysse HA fillers and international brands. International revenue is expected to reach 10% in 2026.

• Estyme HA fillers launched in Europe in Q2; two more Evolysse formulations are planned over the next few years, within a pipeline of three products slated for introduction over four years.

• Revenue grew 14% year to date through Q3 2026, with healthy growth across toxin, fillers and international markets.

Aesthetics market conditions

• U.S. toxin market growth was estimated in the upper-single digits in Q3; consumer demand among households earning $100,000 or more was described as strong.

• Fillers stabilized in 2026 at roughly flat to slight growth by units; management estimated patient volume growth could reach mid- to high-single digits as patients use less product per visit.

• GLP-1 patients are seeking treatment for volume loss; Evolysse is the only HA with a GLP-1 label mention, supporting targeted clinic media campaigns.

Product differentiation and commercial strategy

• Jeuveau growth was attributed to Phase III head-to-head evidence, a JAMA-published clinician study, medical education for nearly 16,000 clinicians and a rewards program nearing 2 million consumers, with nearly 70% repeat treatment.

• Evolysse had been purchased by more than 3,500 facilities within five quarters; reorder rates were approaching Jeuveau levels despite only two formulations being available.

• Sculpt is expected to launch in Q1 2027 and is positioned as the flagship Evolysse product; Evolysse Lips is planned for 2028. Sculpt addresses a market segment estimated at 40%-50%.

• A growth-rebate bundling program ran in H1 2026 and is repeating in H2, complementing account benefits such as co-branded media; participating accounts were the fastest-growing part of the business.

• The SMS-based Evolus Rewards program gives consumers $40 off each Jeuveau or Evolysse treatment and sends clinic-branded reminders; nearly 70% repeat-treatment rates reflect clinic alignment, according to management.